NDC 00173-0941-39: Hibsago Bepirovirsen 150 mg/mL Injection, Solution, Carton of 2 Syringes
This is a package of 2 syringes of Hibsago Bepirovirsen 150 mg/mL Injection, Solution from GlaxoSmithKline LLC, first listed with the FDA Oct 2026 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.
NDC database record
One package, one record: these facts belong to NDC 0173-0941-39 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 0173 labeler · 0941 product · 39 package
- Package marketed since
- Oct 20, 2026
- Sample package
- No — commercial package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 0173094139 8
- FDA record last changed
- Nov 21, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 2754988
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 00173-0941-39 You're viewing this Main listing | 2 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE | 2026-10-20 | — | Active |
| 00173-0941-66 0173-0941-66 | 2 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE Sample | 2026-10-20 | — | Active |
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 00173-0941-66?
What NDC number is used to bill for this package of Hibsago Bepirovirsen 150 mg/mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Hibsago 150 mg/mLthis 00173-0941-39 | GlaxoSmithKline | 2 syringes | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
3 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from GlaxoSmithKline LLC labeler code 00173
- Jesduvroq daprodustat 8 mg Tablet, Film Coated NDC 0173-0914-13
- Zejula niraparib 300 mg Tablet, Film Coated NDC 0173-0915-13
- Breo Ellipta fluticasone furoate and vilanterol trifenatate 50 ug; 25 ug Powder NDC 0173-0916-10
- Blujepa gepotidacin 750 mg Tablet, Film Coated NDC 0173-0922-38
- Exdensur depemokimab 100 mg/mL Injection, Solution NDC 0173-0927-42
- Valtrex valacyclovir hydrochloride 500 mg Tablet, Film Coated NDC 0173-0933-08
- Wellbutrin SR bupropion hydrochloride 100 mg Tablet, Film Coated NDC 0173-0947-55
- Utebzi Tebipenem Pivoxil 300 mg Tablet, Film Coated NDC 0173-0956-76
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🚨 Boxed Warning ▾
WARNING: ON-TREATMENT HEPATIC FLARES AND THROMBOCYTOPENIA On-Treatment Hepatic Flares HIBSAGO may cause on-treatment hepatic flares with increases in ALT of >20-40x ULN associated with decline in HBsAg. Some cases were associated with hyperbilirubinemia. Most occurred in the first 12 weeks of treatment and resolved when treatment was interrupted or permanently discontinued [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6.1 )] .
ALT and total bilirubin must be measured prior to initiation of HIBSAGO and frequently monitored during treatment [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.1 )] . Do not initiate HIBSAGO in patients with evidence of acute hepatic impairment or cirrhosis [see Contraindications ( 4 )] . Interruption of treatment, followed by reducing the dose or discontinuation of HIBSAGO, may be necessary based on the results of liver laboratory tests [see Dosage and Administration ( 2.4 )] .
Thrombocytopenia HIBSAGO may cause reductions in platelet counts that may result in sudden and unpredictable thrombocytopenia, which can be life-threatening. Prior to starting HIBSAGO, obtain a platelet count to ensure the patient is eligible for treatment [see Contraindications ( 4 )] . HIBSAGO is contraindicated in patients with a platelet count below 100 x 10 9 /L prior to initiation of treatment.
During treatment, monitor platelet counts weekly if values are 75 x 10 9 /L or greater, and more frequently if values are less than 75 x 10 9 /L [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.2 )] . If a patient develops signs or symptoms of thrombocytopenia, obtain a platelet count as soon as possible. The patient should not receive additional doses of HIBSAGO unless platelet counts return to 100 x 10 9 /L or greater.
If platelet count falls below 50 x 10 9 /L, treatment with HIBSAGO should be permanently discontinued [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.2 )] . WARNING: ON-TREATMENT HEPATIC FLARES AND THROMBOCYTOPENIA See full prescribing information for complete boxed warning. On-Treatment Hepatic Flares • HIBSAGO may cause on-treatment hepatic flares with increases in ALT of >20-40x ULN associated with decline in HBsAg.
Some cases were associated with hyperbilirubinemia. ( 5.1 ) • Evaluating liver laboratory enzymes prior to treatment and periodic monitoring during treatment is necessary for appropriate dosing. ( 2.4 , 5.1 ) Thrombocytopenia • HIBSAGO may cause reductions in platelet count that may result in sudden and unpredictable thrombocytopenia, which can be life‑threatening.
( 5.2 ) • Evaluating platelet levels prior to treatment and periodic monitoring during treatment is necessary for appropriate dosing. ( 2.4 , 4 , 5.2 )
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE HIBSAGO is indicated in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic hepatitis B virus (HBV) infection in adult patients without cirrhosis: • who have been on NrtI therapy for at least 6 months and have suppressed HBV deoxyribonucleic acid (DNA), and • who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test [see Dosage and Administration ( 2.2 )] . HIBSAGO is a hepatitis B virus (HBV) mRNA-directed antisense oligonucleotide (ASO) indicated in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic HBV infection in adult patients without cirrhosis: • who have been on NrtI therapy for at least 6 months and have suppressed HBV deoxyribonucleic acid (DNA), and • who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test.
( 2.2 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION • Refer to the full prescribing information for additional important dosage information. • HIBSAGO is administered by subcutaneous injection and must be used in combination with NrtI therapy. ( 2.3 ) • Weeks 1 and 2: The recommended dosage of HIBSAGO is 300 mg (administered as two 150 mg subcutaneous injections) twice a week allowing 3 or 4 days between each dose. ( 2.3 ) • Weeks 3 to 24: The recommended dosage of HIBSAGO is 300 mg (administered as two 150 mg subcutaneous injections) once a week on the same day each week.
( 2.3 ) • Laboratory tests must be measured prior to, during, and following discontinuation of treatment. ( 2.2 , 2.4 ) • Dosage modification is recommended in patients experiencing elevated liver laboratory values, platelet count reductions or eGFR decline. ( 2.4 )
2.1Dosage and Administration Overview • HIBSAGO therapy should be prescribed only when appropriate laboratory monitoring can be performed to manage the treatment regimen. Close laboratory monitoring is required to assess for toxicities that may necessitate dose modification, treatment interruption, or permanent discontinuation of HIBSAGO [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.1 , 5.2 , 5.3 )] . • HIBSAGO must be administered under the guidance and supervision of a healthcare provider for the initial dose to ensure proper injection technique. • Patients or caregivers may administer HIBSAGO after their healthcare provider determines that it is appropriate and with medical follow-up, including laboratory testing.
Healthcare providers must provide proper training in subcutaneous injection technique before the patient or caregivers can administer HIBSAGO [see Dosage and Administration ( 2.5 )] . The maximum recommended duration of HIBSAGO treatment is 24 weeks [see Dosage and Administration ( 2.5 , 2.7 )] .
2.2Testing Prior to Initiation for Patient Selection Prior to initiation of HIBSAGO for treatment of chronic HBV infection, test all patients to quantify HBsAg levels in serum or plasma to identify patients with baseline HBsAg levels less than or equal to 3,000 IU/mL [see Indications and Usage ( 1 )] . In addition, test patients for HBV DNA, ALT, AST, bilirubin, platelet count, urine albumin-creatinine ratio (uACR), and estimated glomerular filtration rate (eGFR) prior to initiation of treatment and as directed while on treatment and following treatment completion [see Indications and Usage ( 1 ), Dosage and Administration ( 2.4 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 , 5.2 , 5.3 )] .
Information on FDA-authorized tests for the quantification of HBsAg levels is available at: http://www.fda.gov/CompanionDiagnostics .
2.3Recommended Dosage HIBSAGO is for subcutaneous use only [see Dosage and Administration ( 2.5 )] . The maximum recommended duration of HIBSAGO treatment is 24 weeks [see Dosage and Administration ( 2.7 )] . HIBSAGO must be used in combination with NrtI therapy.
Refer to the NrtI prescribing information for additional information. Weeks 1 and 2 The recommended dosage of HIBSAGO is 300 mg (administered as two 150 mg subcutaneous injections) twice a week allowing 3 or 4 days between each dose. Weeks 3 to 24 The recommended dosage of HIBSAGO is 300 mg (administered as two 150 mg subcutaneous injections) once a week on the same day each week.
Early cessation of HIBSAGO may be considered in patients who have not achieved HBsAg <1 IU/mL by Treatment Week 12 [see Clinical Studies ( 14 )] .
2.4Laboratory Monitoring and Dosage Modifications for Adverse Reactions During treatment with HIBSAGO, laboratory test monitoring is required to detect and manage adverse reactions. Based on laboratory test values, adjustments to HIBSAGO dosage, treatment interruption, and increased frequency of laboratory test monitoring may be required as described in Tables 1 , 2 , and 3 . Dosage Modifications Based on ALT and Total Bilirubin Values Table 1 displays the recommended ALT and to… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Injection: 150 mg/mL of bepirovirsen as a clear, colorless to yellow sterile solution with no visible particulates in a single-dose prefilled glass syringe within a safety syringe device. Injection: 150 mg/mL solution in a single‑dose, prefilled syringe
⛔ Contraindications ▾
4 CONTRAINDICATIONS HIBSAGO is contraindicated in patients: • with acute hepatic impairment, or cirrhosis who have mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C) [see Warnings and Precautions ( 5.1 )] . • with a platelet count below 100 x 10 9 /L prior to initiation of treatment [see Warnings and Precautions ( 5.2 )] . • Patients with acute hepatic impairment, or cirrhosis who have mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B or C) ( 4 , 5.1 ) • Patients with platelet count below 100 x 10 9 /L prior to initiation of treatment ( 4 , 5.2 )
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS • Worsening renal function has been observed with HIBSAGO. Evaluating eGFR and urine albumin‑creatinine ratio (uACR) prior to treatment and monitoring eGFR during treatment is necessary for appropriate dosing. ( 2.4 , 5.3 ) • Serious inflammatory and immune adverse reactions have occurred.
If signs and symptoms suggestive of vasculitis/immune-associated events occur, and no alternative cause is identified, permanently discontinue treatment with HIBSAGO. ( 5.4 ) • A serious adverse reaction has been observed with improper administration of HIBSAGO. Ensure that injection sites are rotated from one week to the next and that the two injections are separated by at least 2 inches (5 cm).
( 5.5 ) • Exacerbations of HBV may occur after discontinuation of anti-HBV therapy. Frequent monitoring is important to assess the need for resumption of HBV treatment. ( 5.6 ) • Patients taking nucleos(t)ide analog reverse transcriptase inhibitor therapy for HIV-1 and HBV coinfection must not stop this therapy unless an HIV healthcare provider has directed them to do so.
( 5.7 ) • HIBSAGO is not recommended in patients with Hepatitis D Virus (HDV) coinfection due to the potential for an exacerbated risk of clinically significant ALT increases. ( 5.8 )
5.1On-Treatment Hepatic Flares During treatment with HIBSAGO, increases in ALT ≥3 x ULN to 69 x ULN were observed in clinical trials [see Adverse Reactions ( 6.1 )] . Most ALT increases occurred in the first 12 weeks of treatment (typically between Weeks 5 to 10), started to resolve within 2 weeks, and were not associated with any clinical signs or symptoms of liver dysfunction. The ALT increases were temporally associated with a preceding or concurrent decline in HBsAg suggesting host immune response.
Two percent of participants receiving HIBSAGO had ALT increases ≥20 x ULN that resolved when treatment was interrupted or permanently discontinued. There have been isolated cases of ALT increases associated with an increase in total bilirubin up to 4 x ULN that resolved when treatment was permanently discontinued. ALT and total bilirubin must be measured prior to initiation of treatment.
Do not initiate HIBSAGO in patients with evidence of acute hepatic impairment or cirrhosis [see Contraindications ( 4 )] . During and after HIBSAGO treatment, follow the recommended monitoring for ALT and total bilirubin and the treatment recommendations as specified in Table 1 [see Dosage and Administration ( 2.4 )]. In all patients, the minimum recommended on-treatment monitoring of ALT and total bilirubin is weekly through Week 12 and every other week from Weeks 12 through 24, but more frequent monitoring may be necessary.
In addition, HIBSAGO dose reduction or temporary or permanent discontinuation of HIBSAGO may be necessary based on the results of liver laboratory testing. In all patients with abnormal values at the time of HIBSAGO discontinuation, obtain ALT and total bilirubin values at 4, 12, and 24 weeks post-treatment to assess recovery of ALT values to within the normal range, as appropriate [see Dosage and Administration ( 2.4 )].
5.2Thrombocytopenia HIBSAGO may cause reductions in platelet count at any time during treatment that may result in sudden and unpredictable thrombocytopenia that can be life-threatening. In the HIBSAGO clinical trials, two participants reported serious adverse reactions of thrombocytopenia <50 × 10⁹/L, including one participant with immune thrombocytopenia [see Adverse Reactions ( 6.1 )] . In addition, a gradual, dose-dependent decline in platelet count was observed in most patients that continued to worsen while on HIBSAGO.
Platelet Monitoring and Dosing Platelet count must be measured prior to initiation of treatment. Do not initiate HIBSAGO in patients with a platelet count below 100 x 10 9 /L [see Contraindications ( 4 )] . In patients with platelet count below the normal range but ≥100 x 10 9 /L, rule out cirrhosis before initiating HIBSAGO [see C… [Excerpted — this section continues on DailyMed.]
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following adverse reactions are described in more detail in the Warnings and Precautions section of the labeling: • On-Treatment Hepatic Flares [see Warnings and Precautions ( 5.1 )] . • Thrombocytopenia [see Warnings and Precautions ( 5.2 )] . • Worsening Renal Function [see Warnings and Precautions ( 5.3 )] . • Inflammatory and Immune Effects [see Warnings and Precautions ( 5.4 )] . • Serious Adverse Reaction with Improper Administration [see Warnings and Precautions ( 5.5 )] . The most common adverse reactions (incidence ≥10%) are injection site reactions, pyrexia, fatigue, and headache.
( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
6.1Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of HIBSAGO in the treatment of chronic HBV infection has been evaluated in two pooled, Phase 3, placebo-controlled randomized trials (B‑Well 1 and B‑Well 2) in which 1,223 participants received at least one dose of HIBSAGO (300 mg subcutaneously, twice weekly during Weeks 1 and 2, and once weekly during Weeks 3 to 24) and 611 participants received matching placebo.
The most common adverse reactions (≥10%), excluding laboratory abnormalities, reported with HIBSAGO included injection site reactions, pyrexia, fatigue, and headache. In the pooled B-Well 1 and B-Well 2 trials, 3% of participants receiving HIBSAGO and <1% of participants receiving placebo discontinued due to adverse events. The incidence of adverse reactions in the pooled safety data set (Weeks 1‑36) with HIBSAGO is shown in Table 4 .
Table 4. Adverse Reactions a (All Grades) Reported in ≥3% of HIBSAGO Recipients and at a Frequency ≥2% Greater than Placebo, B-Well 1 and B-Well 2 Trials (Weeks 1-36) a Frequencies of adverse reactions are based on all adverse events, regardless of investigator assessment of causality, excluding laboratory abnormalities reported as adverse events (see Table 6 for laboratory abnormalities). b See Table 5 for a summary of the different types of injection site reactions. c Fatigue includes the preferred terms asthenia, fatigue, malaise, lethargy and sluggishness.
Adverse Reaction HIBSAGO N = 1,223 Placebo N = 611 Injection Site Reactions (all types) b 57% 15% Pyrexia 20% 4% Fatigue c 16% 8% Headache 14% 12% Myalgia 8% 4% Nausea or Vomiting 5% 3% Erythema 5% <1% Pruritus 5% 2% Influenza-like illness 4% 2% Rash 3% 1% Contusion 3% 1% Cutaneous Vasculitis Adverse reactions of biopsy-confirmed vasculitis occurred in two participants treated with HIBSAGO. One participant developed arthralgia, lower limb edema, and purpuric lesions at Treatment Week 2. The second participant developed a pruritic circular lesion on the left lower limb at Treatment Week 14 which progressed to bilateral lower limb pruritic scaly lesions on Treatment Week 17.
For both cases, skin biopsy confirmed leukocytoclastic vasculitis, and the events resolved with corticosteroid treatment after permanent discontinuation of HIBSAGO [see Warnings and Precautions ( 5.4 )] . Injection Site Reactions (ISRs) ISRs were the most common adverse reactions reported with HIBSAGO. The most commonly reported ISRs (all grades) in the pooled safety data set (Weeks 1‑36) are presented in Table 5 .
The frequency and severity of injection site reactions decreased over time, and 99% of injection site reactions reported in HIBSAGO recipients were mild to moderate in severity. Table 5: Injection Site Reactions a (All Grades) Reported in ≥3% of HIBSAGO Recipients and at a Frequency ≥2% Greater than Placebo, B-Well 1 and B-Well 2 Trials (Weeks 1-36) Pooled Injection Site Reaction Categories b HIBSAGO N = 1,223 Placebo N = 611 a Frequencies of injection… [Excerpted — this section continues on DailyMed.]
🔄 Drug Interactions ▾
7 DRUG INTERACTIONS • Monitor patients for signs of bleeding and thrombocytopenia if HIBSAGO is taken concomitantly with anticoagulants, antiplatelets or drugs that decrease platelet count. ( 7.1 ) • Monitor patients for signs of worsening renal function during concomitant administration of HIBSAGO with drugs that may impair renal function. ( 7.2 ) • Concomitant administration of HIBSAGO and peginterferon alfa-2a is not recommended. ( 7.3 )
7.1Anticoagulants, Antiplatelets, and Drugs that Decrease Platelet Count Monitor patients for signs of bleeding and thrombocytopenia if HIBSAGO is taken concomitantly with anticoagulants, antiplatelets, or drugs that decrease platelet count [see Warnings and Precautions ( 5.2 ), Adverse Reactions ( 6.1 )] .
7.2Drugs that Impair Renal Function Monitor patients for signs of worsening renal function during concomitant administration of HIBSAGO with drugs that may impair renal function. Refer to individual drug information before prescribing [see Warnings and Precautions ( 5.3 ), Adverse Reactions ( 6.1 )] .
7.3Peginterferon Alfa-2a Concomitant administration of HIBSAGO and peginterferon alfa‑2a is not recommended due to the potential for an exacerbated risk of increased ALT, decreased platelet count, and immune-mediated effects.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS
8.1Pregnancy Risk Summary There are insufficient data on the use of HIBSAGO in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental or reproductive effects were observed when bepirovirsen was administered subcutaneously to mice and rabbits at less than 1 (mouse) and approximately 3 (rabbits) times the maximum recommended human dose (MRHD), based on body surface area (BSA) comparisons (see Data) .
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data: No adverse effects on embryofetal development, parturition, or on the postnatal development of the offspring were observed following subcutaneous administration of bepirovirsen to pregnant mice during organogenesis and throughout pregnancy and lactation [Gestation day (GD) 0 to 15 and from GD 6 to lactation day (LD) 21], at 0.7 times the MRHD based on BSA comparison.
Bepirovirsen was also administered subcutaneously to pregnant rabbits at doses up to 25 mg/kg every other day during organogenesis (GD 6 to 18). Reduced fetal weights associated with maternal toxicity were observed at approximately 3 times the MRHD based on BSA comparison.
8.2Lactation Risk Summary There are insufficient data on the presence of bepirovirsen or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. Bepirovirsen was detectable in the milk of lactating mice without an effect on offspring (see Data) . When a drug is present in animal milk, it is likely that the drug will be present in human milk.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for HIBSAGO and any potential adverse effects on the breastfed child from HIBSAGO or from the underlying maternal condition. Data Animal Data: No adverse effects on lactation or on the offspring were observed following subcutaneous administration of bepirovirsen to pregnant and lactating mice (GD 6 through LD 21) at 0.7 times the MRHD based on BSA comparison. Although bepirovirsen was detected in the milk of lactating mice (on LD 10), systemic exposure of bepirovirsen in the offspring via milk was negligible.
8.4Pediatric Use The safety and effectiveness of HIBSAGO have not been established in patients less than 18 years of age.
8.5Geriatric Use Of the total number of patients who received treatment with HIBSAGO in the B‑Well 1 and B‑Well 2 trials, 128 (10%) were 65 years of age and older. The efficacy response was generally higher for age <65 versus that for age ≥65 years [see Clinical Studies ( 14 )] . No overall differences in safety of HIBSAGO were observed between patients 65 years of age and older and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.
In the B-Well 1 and B-Well 2 trials, 21 (1%) participants were 75 years of age and older. Differences in efficacy in this age group versus younger adult patients cannot be determined due to the small number of participants.
8.6Renal Impairment No dosage adjustment is recommended in patients with mild renal impairment (eGFR 60 to 89 mL/min/1.73m 2 ) [see Clinical Pharmacology ( 12.3 )] . Insufficient data are available on the safety of HIBSAGO in patients with moderate or severe renal impairment or end stage renal disease (eGFR less than or equal to 59 mL/min/1.73m 2 ). HIBSAGO can cause worsening renal function [see Warnings and Precautions ( 5.3 )] .
8.7Hepatic Impairment The safety and efficacy of HIBSAGO in patients with cirrhosis have not been established. The use of HIBSAGO is contraindicated in chronic hepatitis B patients with acut… [Excerpted — this section continues on DailyMed.]
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are insufficient data on the use of HIBSAGO in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental or reproductive effects were observed when bepirovirsen was administered subcutaneously to mice and rabbits at less than 1 (mouse) and approximately 3 (rabbits) times the maximum recommended human dose (MRHD), based on body surface area (BSA) comparisons (see Data) .
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data: No adverse effects on embryofetal development, parturition, or on the postnatal development of the offspring were observed following subcutaneous administration of bepirovirsen to pregnant mice during organogenesis and throughout pregnancy and lactation [Gestation day (GD) 0 to 15 and from GD 6 to lactation day (LD) 21], at 0.7 times the MRHD based on BSA comparison.
Bepirovirsen was also administered subcutaneously to pregnant rabbits at doses up to 25 mg/kg every other day during organogenesis (GD 6 to 18). Reduced fetal weights associated with maternal toxicity were observed at approximately 3 times the MRHD based on BSA comparison.
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of HIBSAGO have not been established in patients less than 18 years of age.
🧓 Geriatric Use ▾
8.5Geriatric Use Of the total number of patients who received treatment with HIBSAGO in the B‑Well 1 and B‑Well 2 trials, 128 (10%) were 65 years of age and older. The efficacy response was generally higher for age <65 versus that for age ≥65 years [see Clinical Studies ( 14 )] . No overall differences in safety of HIBSAGO were observed between patients 65 years of age and older and younger adult patients, but greater sensitivity of some older individuals cannot be ruled out.
In the B-Well 1 and B-Well 2 trials, 21 (1%) participants were 75 years of age and older. Differences in efficacy in this age group versus younger adult patients cannot be determined due to the small number of participants.
🆘 Overdosage ▾
10 OVERDOSAGE Single doses of HIBSAGO 600 mg (2 times the recommended dose) were administered subcutaneously in a clinical trial to 5 healthy adults. Two participants developed tolerability issues at this dose, with symptoms including headache, nausea, vomiting, myalgia, and dizziness which lasted 24 to 48 hours despite symptomatic treatment. There is no specific treatment for an overdose with HIBSAGO.
If overdose occurs, the patient should be treated supportively with appropriate monitoring. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action HIBSAGO is an antiviral drug against HBV [see Microbiology ( 12.4 )] .
12.2Pharmacodynamics Exposure Response Within the range of bepirovirsen exposures achieved at the dosing regimen in B-Well 1 and B-Well 2 trials, variability in bepirovirsen plasma exposure was not identified as a determinant of treatment response at Week 72. Immunostimulant Activity In nonclinical studies, bepirovirsen exhibited innate immune activity in a sequence-specific, human toll-like receptor 8 (hTLR8)-dependent manner, with no activity observed at other pattern recognition receptors tested. This was demonstrated in an hTLR8-overexpressing cell line and confirmed in transgenic hTLR8 knock-in mice.
Compared to wild-type mice, hTLR8 knock-in mice showed increased proinflammatory cytokine expression upon bepirovirsen treatment. This immunostimulatory activity was predominantly localized to hepatic macrophages and Kupffer cells, with induction of cytokines including TNF-α, IL-12p40, and CXCL10. In clinical studies, administration of HIBSAGO was associated with increases in innate immune markers of activation and trafficking, which included cytokines and chemokines (e.g., interleukin12, tumor necrosis factor, interferon gamma and CXC motif chemokine ligand 9 and 10).
Treatment with HIBSAGO also increased total IgM. In addition, treatment with HIBSAGO led to immunophenotypic changes in peripheral B and T cells (including increases in Ki67 positive B and T cells and increases in granzyme B positive cluster of differentiation 8, T cell frequencies). The contribution of immunostimulatory activity to antiviral activity at therapeutic concentrations in humans has not been fully determined.
Cardiac Electrophysiology At supratherapeutic doses of 450 or 600 mg (1.5 and 2 times the recommended dosage) of HIBSAGO, clinically significant QTc interval prolongation was not observed.
12.3Pharmacokinetics The pharmacokinetic parameters of bepirovirsen 300 mg are summarized in Table 7 . Table 7. Pharmacokinetic Properties of Bepirovirsen C max = maximum plasma concentration; AUC 0-tau = area under the time concentration curve from 0 to dosing interval; T max = time to peak concentration; Vss = Volume of Distribution at steady‑state. a Pharmacokinetic parameters are presented as arithmetic mean (SD), derived from population PK model simulations at steady state following subcutaneous administration of HIBSAGO 300 mg weekly in participants with chronic HBV infection (CHB). b observed median (min-max) c Pharmacokinetic parameters are presented as geometric mean (CV%) from post-hoc individual estimates from Phase 3 population PK model.
General Information Exposure C max (mcg/mL) a 9.14 (2.19) AUC 0-tau (mcg*hour/mL) a 102 (34.3) C trough (mcg/mL) a 0.022 (0.045) Dose proportionality Exposure increased in proportion to dose over the range of 150 to 300 mg weekly dosing Time to steady state Steady state concentration is reached by Day 8 following 300 mg weekly dosing with loading doses during Weeks 1 and 2 Accumulation No accumulation was observed with 300 mg weekly dosing for 24 weeks Absorption T max , (hours) b 3 (2-5) Distribution V ss /F (L) c 73 (46.3) Plasma Protein Binding 99% at 5 mcg/mL 95% at 150 mcg/mL Elimination Major route of elimination Metabolism Terminal Half-life (days) b 29 (8-192) Clearance/F (L/hour) c 3.05 (25.7) Metabolism Primary Pathway Metabolized in tissues by endonucleases to form shorter oligonucleotides that are then substrates for additional metabolism by exonucleases Excretion Urine Oligonucleotide fragments are expected to be excreted by the kidney Specific Populations Based on population pharmacokinetic analyses, following subcutaneous administration, there were no clinically meaningful changes in the pharmacokinetics of bepirovirsen by race (Asian, Black, White, Other), ethnicity, age (18-87 years old), sex, body weight (39 kg to 148 kg), injection site location (thigh, upper arm, abdomen) a… [Excerpted — this section continues on DailyMed.]
🧬 Mechanism of Action ▾
12.1Mechanism of Action HIBSAGO is an antiviral drug against HBV [see Microbiology ( 12.4 )] .
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING HIBSAGO (bepirovirsen) injection is a sterile, preservative-free, clear, colorless to yellow solution for subcutaneous use. The syringes are not made with natural rubber latex. Each single‑dose prefilled syringe delivers 150 mg of bepirovirsen in 1 mL of solution.
HIBSAGO injection is supplied as 150 mg/mL, single-dose, prefilled glass syringe with attached 27-gauge, 0.5 inch (12.7 mm) needle with a needle guard in cartons of 2 (NDC 0173-0941-39). Storage and Handling Prior to Dispensing: Store in a refrigerator at 36°F to 46°F (2°C to 8°C). Do not freeze.
Store in the original carton to protect from light. Do not shake. Following Dispensing: Store HIBSAGO at room temperature up to 86°F (30°C) for 12 weeks.
Do not freeze. Store in the original carton to protect from light. Do not shake.
Discard if the expiry date has passed, or it has been 12 weeks since carton was received, whichever comes first. HIBSAGO injection must be administered within 6 hours once removed from the carton. Discard if not administered within 6 hours.
📋 Description ▾
11 DESCRIPTION HIBSAGO (bepirovirsen) injection is a hepatitis B virus (HBV) messenger RNA-directed antisense oligonucleotide. The chemical name of bepirovirsen sodium is: all-P-ambo- 2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine, nonadeca sodium salt.
The molecular formula of bepirovirsen sodium is C 230 H 290 N 88 Na 19 O 115 P 19 S 19 and its molecular weight is 7761.9. The structural formula is shown below. HIBSAGO injection for subcutaneous use is a sterile, preservative-free, clear, colorless to yellow solution with no visible particulates.
HIBSAGO injection is supplied as two, 1-mL, single-dose, prefilled syringes with a 0.5 inch (12.7 mm), 27-gauge, stainless steel needle assembled with a needle guard. Each 1 mL delivers 150 mg bepirovirsen, equivalent to 159 mg of bepirovirsen sodium, in 1 mL water for injection and may contain hydrochloric acid or sodium hydroxide to adjust to pH 8. Bepirovirsen sodium chemical structure
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use). Give patients the Medication Guide for HIBSAGO. On-Treatment Hepatic Flares Inform patients that HIBSAGO may cause elevations in ALT.
Advise patients to contact their healthcare provider immediately if they experience abdominal discomfort, dark urine, or jaundice and the importance of complying with laboratory monitoring during and after treatment with HIBSAGO [see Warnings and Precautions ( 5.1 )] . Thrombocytopenia Inform patients that HIBSAGO may cause reductions in platelet count that may result in thrombocytopenia. Instruct patients to immediately report any signs of unusual or prolonged bleeding to their physician.
Advise patients of the importance of complying with laboratory monitoring during and after treatment with HIBSAGO [see Warnings and Precautions ( 5.2 )] . Worsening Renal Function Inform patients that HIBSAGO may cause worsening of renal function. Advise patients of the importance of complying with laboratory monitoring during and after treatment with HIBSAGO [see Warnings and Precautions ( 5.3 )] .
Inflammatory and Immune-Mediated Adverse Reactions Inform patients that HIBSAGO may cause inflammatory and immune effects. Advise patients to contact their healthcare provider if they experience influenza‑like symptoms with events such as purpuric leg rashes, cutaneous leukocytoclastic vasculitis, dermatitis, pruritus/erythematous plaque, and polyarthralgia [see Warnings and Precautions ( 5.4 )] . Administration Instruction Train patients and caregivers on the importance of proper subcutaneous administration technique, the necessity of rotating injection sites and how to use the prefilled syringe.
Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use HIBSAGO [see Warnings and Precautions ( 5.5 )] . HBV Exacerbation after Discontinuation of HBV Therapy Inform patients that severe acute exacerbations of HBV may occur after stopping all anti-HBV therapy. If NrtI therapy is discontinued after completing HIBSAGO treatment, advise patients of the importance of frequent monitoring to assess the possible need for resumption of HBV treatment [see Warnings and Precautions ( 5.6 )] .
Risks in Patients with HBV/HIV Coinfection Advise patients living with HIV who are taking NrtI therapy for both HIV and HBV to not discontinue NrtI therapy except under the direct supervision of an HIV healthcare provider [see Warnings and Precautions ( 5.7 )] . Transmission of HBV Inform patients that it is not known if therapy with HIBSAGO will prevent transmission of HBV, and that appropriate precautions to prevent transmission of the hepatitis B virus should be taken [see Warnings and Precautions ( 5.9 )] . Trademarks are owned by or licensed to the GSK group of companies.
Manufactured for GlaxoSmithKline Durham, NC 27701 ©2026 GSK group of companies or its licensor. HBS:1PI
💬 Medication Guide ▾
MEDICATION GUIDE HIBSAGO (hib sah' goe) (bepirovirsen) injection, for subcutaneous use What is the most important information I should know about HIBSAGO? HIBSAGO may cause serious side effects, including: • flare-ups in liver enzyme levels during treatment. HIBSAGO may cause increases in liver function blood tests.
Tell your healthcare provider right away if you get any of these symptoms: o upper right stomach pain o dark or “tea-colored” urine o yellowing of your skin or the white part of your eyes o nausea or vomiting o loss of appetite • low platelet counts (thrombocytopenia) . HIBSAGO may cause your blood platelet levels to drop at any time during your treatment. When your platelet count is too low, your body cannot form blood clots properly.
Low platelet counts can happen suddenly and without warning and can be life-threatening. Stop using HIBSAGO and tell your healthcare provider right away if you get any of these symptoms: o unusual bruising or a rash of tiny reddish-purple spots o bleeding from skin cuts that does not stop or oozes o bleeding from your gums or nose o blood in your urine or stools o abnormal or heavy periods (menstrual bleeding) o sudden severe headaches or neck stiffness o bleeding into the whites of your eyes Your healthcare provider will do blood tests to check your liver and platelet count, before you start HIBSAGO, during treatment, and if you have abnormal blood tests for up to 24 weeks after you stop HIBSAGO.
It is important that you make sure you get these blood tests done. What is HIBSAGO? HIBSAGO is a prescription medicine used with other medicines called nucleos(t)ide analog reverse transcriptase inhibitors (NrtIs), to treat adults with chronic (long-term) hepatitis B virus (HBV) infection without advanced liver disease (cirrhosis): • who have been on NrtI treatment for at least 6 months and have undetectable HBV deoxyribonucleic acid (DNA), and • who have low levels of HBV surface antigen (HBsAg less than or equal to 3,000 IU/mL) Your healthcare provider will perform tests to make sure HIBSAGO is right for you.
It is not known if HIBSAGO is safe and effective in children less than 18 years of age. It is not known if HIBSAGO is safe and effective in people who also have hepatitis C virus (HCV) or hepatitis D virus (HDV) infection. HIBSAGO is not recommended in people with HDV infection as it may increase the chance of flare-ups in liver enzymes.
Who should not use HIBSAGO? Do not use HIBSAGO if you have: • a condition where your liver is currently not working as well as it should • have advanced liver disease (cirrhosis) • low platelet blood counts. Talk to your healthcare provider if you are not sure if you have any of these conditions.
Before using HIBSAGO, tell your healthcare provider about all of your medical conditions, including if you: • have bleeding problems or a history of bleeding problems • have kidney problems • have received an organ transplant • have problems with your immune system (autoimmune disease), or have a history of blood vessel inflammation (vasculitis) • have hepatitis D • are pregnant or plan to become pregnant. It is not known if HIBSAGO will harm your unborn baby. • are breastfeeding or plan to breastfeed. HIBSAGO may pass into your breast milk.
Talk to your healthcare provider about the best way to feed your baby during treatment with HIBSAGO. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using HIBSAGO with certain other medicines may increase the risk of side effects.
Especially tell your healthcare provider if you take: • medicines that prevent your blood from clotting or that lower your blood platelet count. • medicines that may lower your kidney function. • peginterferon alfa-2a. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
How should I use HIBSAGO? Read the detailed Instr… [Excerpted — this section continues on DailyMed.]
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics The pharmacokinetic parameters of bepirovirsen 300 mg are summarized in Table 7 . Table 7. Pharmacokinetic Properties of Bepirovirsen C max = maximum plasma concentration; AUC 0-tau = area under the time concentration curve from 0 to dosing interval; T max = time to peak concentration; Vss = Volume of Distribution at steady‑state. a Pharmacokinetic parameters are presented as arithmetic mean (SD), derived from population PK model simulations at steady state following subcutaneous administration of HIBSAGO 300 mg weekly in participants with chronic HBV infection (CHB). b observed median (min-max) c Pharmacokinetic parameters are presented as geometric mean (CV%) from post-hoc individual estimates from Phase 3 population PK model.
General Information Exposure C max (mcg/mL) a 9.14 (2.19) AUC 0-tau (mcg*hour/mL) a 102 (34.3) C trough (mcg/mL) a 0.022 (0.045) Dose proportionality Exposure increased in proportion to dose over the range of 150 to 300 mg weekly dosing Time to steady state Steady state concentration is reached by Day 8 following 300 mg weekly dosing with loading doses during Weeks 1 and 2 Accumulation No accumulation was observed with 300 mg weekly dosing for 24 weeks Absorption T max , (hours) b 3 (2-5) Distribution V ss /F (L) c 73 (46.3) Plasma Protein Binding 99% at 5 mcg/mL 95% at 150 mcg/mL Elimination Major route of elimination Metabolism Terminal Half-life (days) b 29 (8-192) Clearance/F (L/hour) c 3.05 (25.7) Metabolism Primary Pathway Metabolized in tissues by endonucleases to form shorter oligonucleotides that are then substrates for additional metabolism by exonucleases Excretion Urine Oligonucleotide fragments are expected to be excreted by the kidney Specific Populations Based on population pharmacokinetic analyses, following subcutaneous administration, there were no clinically meaningful changes in the pharmacokinetics of bepirovirsen by race (Asian, Black, White, Other), ethnicity, age (18-87 years old), sex, body weight (39 kg to 148 kg), injection site location (thigh, upper arm, abdomen) and anti-drug antibodies (ADA) status.
Renal Impairment: Bepirovirsen pharmacokinetics were similar between patients with CHB with an eGFR 60 to 89 mL/min/1.73m 2 compared to patients with an eGFR ≥90 mL/min/1.73 m 2 . Insufficient data are available in patients with moderate or severe renal impairment. Hepatic Impairment: The pharmacokinetics of bepirovirsen have not been evaluated in CHB patients with hepatic impairment (Child-Pugh Class A, B, or C) [see Contraindications ( 4 )] .
There is a 33% reduction in C max and a 31% reduction in AUC 0-∞ in participants with moderate hepatic impairment (Child‑Pugh Class B) but without HBV infection when compared to participants with normal hepatic function. Drug Interaction Studies No formal clinical drug interaction studies have been conducted with HIBSAGO. In clinical trials, concomitant administration of HIBSAGO with a NrtI did not result in changes in bepirovirsen exposure.
In addition, HIBSAGO did not impact NrtI exposure. Based on in vitro study results, HIBSAGO is not a substrate, inducer or inhibitor of major cytochrome P450 (CYP) enzymes, or drug transporters; therefore, clinically relevant pharmacokinetic interactions are not expected.
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics Exposure Response Within the range of bepirovirsen exposures achieved at the dosing regimen in B-Well 1 and B-Well 2 trials, variability in bepirovirsen plasma exposure was not identified as a determinant of treatment response at Week 72. Immunostimulant Activity In nonclinical studies, bepirovirsen exhibited innate immune activity in a sequence-specific, human toll-like receptor 8 (hTLR8)-dependent manner, with no activity observed at other pattern recognition receptors tested. This was demonstrated in an hTLR8-overexpressing cell line and confirmed in transgenic hTLR8 knock-in mice.
Compared to wild-type mice, hTLR8 knock-in mice showed increased proinflammatory cytokine expression upon bepirovirsen treatment. This immunostimulatory activity was predominantly localized to hepatic macrophages and Kupffer cells, with induction of cytokines including TNF-α, IL-12p40, and CXCL10. In clinical studies, administration of HIBSAGO was associated with increases in innate immune markers of activation and trafficking, which included cytokines and chemokines (e.g., interleukin12, tumor necrosis factor, interferon gamma and CXC motif chemokine ligand 9 and 10).
Treatment with HIBSAGO also increased total IgM. In addition, treatment with HIBSAGO led to immunophenotypic changes in peripheral B and T cells (including increases in Ki67 positive B and T cells and increases in granzyme B positive cluster of differentiation 8, T cell frequencies). The contribution of immunostimulatory activity to antiviral activity at therapeutic concentrations in humans has not been fully determined.
Cardiac Electrophysiology At supratherapeutic doses of 450 or 600 mg (1.5 and 2 times the recommended dosage) of HIBSAGO, clinically significant QTc interval prolongation was not observed.
🔬 Clinical Studies ▾
14 CLINICAL STUDIES The efficacy of HIBSAGO in the treatment of chronic HBV infection was evaluated in two multi-center, Phase 3, randomized, double-blind, placebo-controlled trials with identical designs (B-Well 1 [NCT05630807] and B-Well 2 [NCT05630820]). All participants were aged ≥18 years, had documented chronic HBV infection for ≥6 months, were receiving stable NrtI therapy (defined as no changes due to loss of virologic control for ≥6 months before the start of the trial and no plans for changes over the duration of the trial), and had serum HBsAg >100 to ≤3,000 IU/mL at screening, HBV DNA <90 IU/mL, and ALT ≤2X the upper limit of normal.
Participants could be either HBeAg-positive or HBeAg-negative at baseline. Participants were excluded from the trial if they had a history, suspicion, or evidence of cirrhosis; co-infection with HCV, HIV, or HDV; history or evidence of potential vasculitis; eGFR ≤60 mL/min/1.73m 2 ; or platelet count <140 x 10 9 /L. Participants were randomized 2:1 to receive HIBSAGO for 24 weeks (300 mg, twice weekly during Weeks 1 and 2, and once weekly during Weeks 3 to 24), or placebo, together with their background NrtI therapy.
The randomization was stratified by HBsAg levels at baseline (HBsAg ≤ 1,000 IU/mL or >1,000 IU/mL to ≤3,000 IU/mL). Each dose of HIBSAGO was administered as two 150 mg subcutaneous injections into the abdomen, thigh, and/or outer area of upper arms. From Week 25 to 48, participants continued to receive their NrtI therapy without HIBSAGO or placebo.
At Week 48, participants who met the prespecified NrtI cessation eligibility criteria discontinued NrtI therapy. To be eligible for NrtI cessation, participants had to have no evidence of cirrhosis at Week 36, have HBV DNA <LLOQ and HBsAg not detected (as assessed by the qualitative HBsAg assay) from Week 24 to 46 (allowing for single blips to any level) in the absence of rescue medication (defined as any medication with proven anti-HBV activity newly initiated for the purpose of HBV control), be HBeAg negative with ALT values ≤2x ULN at Week 46, and have remained on stable NrtI therapy for the preceding 48 weeks.
Blips were defined as transiently quantifiable HBV DNA (≥LLOQ) or detected HBsAg at a single visit. In Trial B-Well 1, a total of 981 participants were randomized (2:1) to receive either HIBSAGO or placebo. In the full analysis set (FAS) of 978 participants who received at least one dose of HIBSAGO or placebo, 70% were male; the mean age was 50 years (range: 21 to 87 years); 68% were Asian, 25% were White, 5% were Black or African American, and 2% were Other; 11% were Hispanic or Latino; 58% were in Asia, 25% were in Europe, 10% were in Latin America, and 7% were in US and Canada; 65% had HBsAg at baseline ≤1,000 IU/mL; 31% were genotype C, 26% were genotype D, 25% were genotype B, 10% were genotype A, 8% were other genotypes; 91% had ALT ≤ULN at baseline; 92% were HBeAg negative at baseline; 41% had been diagnosed with CHB for 20 years or longer, 33% for 10 to 20 years, 15% for 5 to 10 years, and 11% were diagnosed less than 5 years ago.
In Trial B-Well 2, a total of 857 participants were randomized (2:1) to receive either HIBSAGO or placebo. In the FAS of 856 participants who received at least one dose of HIBSAGO or placebo, 72% were male; the mean age was 49 years (range: 22 to 79 years); 68% were Asian, 27% were White, 4% were Black or African American, and 1% were Other; 5% were Hispanic or Latino; 59% were in Asia, 27% were in Europe, 6% were in US and Canada, 4% were in Latin America, and 4% were in Oceania; 61% had HBsAg at baseline ≤1,000 IU/mL; 32% were genotype C, 25% were genotype B, 25% were genotype D, 11% were genotype A, 5% were other genotypes, 2% had unknown genotype; 93% had ALT ≤ULN at baseline; 92% were HBeAg negative at baseline; 42% had been diagnosed with CHB for 20 years or longer, 32% for 10 to 20 years, 16% for 5 to 10 years, and 11% were diagnosed less than 5 years ago.
In each trial, demogr… [Excerpted — this section continues on DailyMed.]
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a 2-year carcinogenicity study in mice, bepirovirsen sodium was administered by subcutaneous injection weekly at doses of 3, 10, and 30 mg/kg (approximately 0.05, 0.2, and 0.5 times the RHD, respectively, based on BSA comparison). In male mice, statistically significant increases in tumor incidences were observed compared to controls in liver (hepatocellular carcinomas at ≥10 mg/kg; hepatocellular adenomas, combined hepatocellular adenomas/carcinomas, hemangiosarcomas, and combined hemangiosarcomas/hemangiomas at 30 mg/kg), in stomach (adenomas and combined adenomas/adenocarcinomas at 30 mg/kg), and at the injection sites (fibrosarcomas at 30 mg/kg).
In female mice, hepatocellular adenoma and combined hepatocellular adenoma/carcinoma were increased at 30 mg/kg. Increased tumor findings have been observed in 2-year carcinogenicity studies in mice dosed subcutaneously with phosphorothioate ASO class drugs; the clinical relevance is unknown. Mutagenesis Bepirovirsen did not exhibit a genotoxic potential in a battery of studies, including an in vitro bacterial reverse mutation (Ames) test, mammalian cell chromosomal aberration test and an in vivo micronucleus test in mice.
Impairment of Fertility No adverse effects on male or female mating or fertility were observed following subcutaneous administration of bepirovirsen to mice up to 0.7 times the MRHD (based on BSA comparison).
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis In a 2-year carcinogenicity study in mice, bepirovirsen sodium was administered by subcutaneous injection weekly at doses of 3, 10, and 30 mg/kg (approximately 0.05, 0.2, and 0.5 times the RHD, respectively, based on BSA comparison). In male mice, statistically significant increases in tumor incidences were observed compared to controls in liver (hepatocellular carcinomas at ≥10 mg/kg; hepatocellular adenomas, combined hepatocellular adenomas/carcinomas, hemangiosarcomas, and combined hemangiosarcomas/hemangiomas at 30 mg/kg), in stomach (adenomas and combined adenomas/adenocarcinomas at 30 mg/kg), and at the injection sites (fibrosarcomas at 30 mg/kg).
In female mice, hepatocellular adenoma and combined hepatocellular adenoma/carcinoma were increased at 30 mg/kg. Increased tumor findings have been observed in 2-year carcinogenicity studies in mice dosed subcutaneously with phosphorothioate ASO class drugs; the clinical relevance is unknown. Mutagenesis Bepirovirsen did not exhibit a genotoxic potential in a battery of studies, including an in vitro bacterial reverse mutation (Ames) test, mammalian cell chromosomal aberration test and an in vivo micronucleus test in mice.
Impairment of Fertility No adverse effects on male or female mating or fertility were observed following subcutaneous administration of bepirovirsen to mice up to 0.7 times the MRHD (based on BSA comparison).
📖 Instructions for Use ▾
INSTRUCTIONS FOR USE HIBSAGO (hib sah' goe) (bepirovirsen) injection, for subcutaneous use 150 mg/mL Prefilled Syringe This Instructions for Use contains information on how to inject HIBSAGO. Read This Section First Read this Instructions for Use before you start using HIBSAGO and each time you refill your prescription. There may be new information.
Before using your HIBSAGO syringe, it is important that your healthcare professional explains your HIBSAGO dosing instructions and shows you (or your caregiver) how to use the syringe the right way. If you do not follow these instructions, you may not get all your medicine. HIBSAGO is for use under the skin only (subcutaneous).
Important Information: • If your prescribed dose is 300 mg , use 2 HIBSAGO syringes and inject both syringes one after the other. • If your prescribed dose is 150 mg , use 1 HIBSAGO syringe to inject your dose. Do not use the HIBSAGO syringe if: • it has been frozen • it has been stored above 86°F (30°C) • it has been dropped or damaged • the security seal on the carton has been broken • the expiration date (EXP) has passed or it has been 12 weeks since you received your HIBSAGO carton, whichever comes first Do not: • shake the HIBSAGO syringes • share or reuse your syringes • expose your syringe to heat or direct sunlight If any of these happen, throw away the HIBSAGO syringe in an FDA-cleared sharps disposal container and use a new HIBSAGO syringe.
Throw away any unused syringes when your healthcare provider tells you that your HIBSAGO treatment is complete. Get to Know Your HIBSAGO Syringes Storage Syringes Stored in Carton • Store HIBSAGO at room temperature up to 86°F (30°C) for up to 12 weeks. • Do not store above 86°F (30°C). • Do not freeze. • Store HIBSAGO in the original carton to protect from light. • Throw away (discard) HIBSAGO in an FDA-cleared sharps disposal container if the expiration date has passed, or it has been 12 weeks since you received your carton, whichever comes first.
Syringes Removed from Carton • HIBSAGO syringes must be injected within 6 hours after you take them out of the carton. If they are not used within 6 hours, throw them away. Keep HIBSAGO and all medicines out of the reach of children.
Contains small parts. A. Prepare Gather Supplies Supplied • 2 HIBSAGO syringes if your dose is 300 mg • 1 HIBSAGO syringe if your dose is 150 mg (keep unused syringe in carton and away from light) Not Supplied • Alcohol swabs • Cotton balls or gauze pads • Adhesive bandages • FDA-cleared sharps disposal container.
(see Section C for disposal instructions) Take Out Your Syringe(s) • Peel off the plastic cover from the corner of the tray. • Hold the middle of the syringe(s) (near the inspection window) and carefully take the syringe(s) out of the trays. • Do not handle the syringe(s) by the white plunger when removing from the tray, or at any point when handling the syringe(s). • Do not remove the gray needle cap(s) at this step. • Do not use the syringe(s) if they have been dropped or damaged. Check Your Syringe(s) • Check the expiration date.
Do not use if the expiration date has passed or it has been 12 weeks since you received your HIBSAGO carton, whichever comes first. • Make sure HIBSAGO has been at room temperature up to 86°F (30°C) for at least 30 minutes before using it. Cold medicine is more painful to inject. • Look at the medicine in the HIBSAGO syringe(s) through the inspection window(s). The medicine should be clear and colorless to yellow with no visible particulates. • It is normal to see air bubbles.
You do not need to do anything about it. • Do not use if HIBSAGO is cloudy, discolored, or has particulates. • Do not shake the syringe(s). Choose Your Injection Site(s) • For a 300 mg dose, you will need 2 injections to complete your dose. For a 150 mg dose, you will need 1 injection to complete your dose. • If you are giving yourself the injection, you can inject into your thighs or stomach (abdomen). • A caregiver can injec… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL NDC 0173-0941-39 HIBSAGO (bepirovirsen) Injection 150 mg/mL Rx Only GSK For subcutaneous use only. If dose is 300 mg, administer 2 syringes, one immediately after the other. If dose is 150 mg, administer 1 syringe only.
Dispense the enclosed Medication Guide to each patient Contents: -Two 1 mL Single-Dose Prefilled Syringes Each syringe delivers 150 mg in 1 mL of HIBSAGO -Instruction for Use (Read carefully) -Medication Guide Prescribing Information ©2026 GSK group of companies or its licensor. Rev. 09/26 62000000105105 Hibsago 150 mg per mL syringe 2 count carton.
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |